Cadila receives US FDA approval to market four drugs in US

Font Size

Print

Feedback

Email

Discuss

Related Articles

Cadila receives US FDA approval to market four dru...HC restrains Cipla from exporting anti-cancer drugDabur OncQuest to expand operations to Pakistan, D...

Mumbai, May 15: : Pharma major Zydus Cadila on Thursday said it has received approval from the US FDA to market four products, including anti-depressant Escitalopram Oxalate tablets in that country.

The group has received the Food and Drug Administration (FDA) approval to market 10, 20, 40, 80 mg of Pravastatin Sodium tablets in the United States, Cadila Healthcare said in a filing to the Bombay Stock Exchange.

Cadila has also received tentative approval from the regulatory body to market Escitalopram Oxalate tablets (5, 10 and 20 mg), Losartam Potassium and Hydrochlorthiazide tablets (50mg/12.5 mg and 100 mg/25 mg) and Anastrazole tablets (1 mg) in the US, the filing said.

The US market of lipid lowering agent Pravastatin Sodium tablet was estimated at 1.9 million dollar in 2007, while the branded sales of anti-depressant Escitalopram Oxalate tablets was at 3 billion dollars.

In 2007, the sale of anti-hypertensive Losartam Potassium and Hydrochlorthiazide tablets stood at 785 million dollar, while Anastrazole tablets had a market of 813 million dollar, the filling added.